Literature DB >> 15791519

Nitazoxanide: a new thiazolide antiparasitic agent.

LeAnne M Fox1, Louis D Saravolatz.   

Abstract

Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. It is given by the oral route with good bioavailability and is well tolerated, with primarily mild gastrointestinal side effects. At present, there are no documented drug-drug interactions. Nitazoxanide has been licensed for the treatment of Giardia intestinalis-induced diarrhea in patients >or=1 year of age and Cryptosporidum-induced diarrhea in children aged 1-11 years. At present, it is pending licensure for treatment of infection due to Cryptosporidium species in adults and for use in treating immunocompromised hosts. It represents an important addition to the antiparasitic arsenal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15791519     DOI: 10.1086/428839

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  100 in total

1.  Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.

Authors:  Janelle M Wright; Linda A Dunn; Zygmunt Kazimierczuk; Anita G Burgess; Kenia G Krauer; Peter Upcroft; Jacqueline A Upcroft
Journal:  Parasitol Res       Date:  2010-06-09       Impact factor: 2.289

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

3.  Norovirus gastroenteritis successfully treated with nitazoxanide.

Authors:  Danish M Siddiq; Hoonmo L Koo; Javier A Adachi; George M Viola
Journal:  J Infect       Date:  2011-08-09       Impact factor: 6.072

Review 4.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

Review 5.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

Review 6.  Epidemiology and management of infectious diseases in international adoptees.

Authors:  Thomas S Murray; M Elizabeth Groth; Carol Weitzman; Michael Cappello
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells.

Authors:  Joachim Müller; Géraldine Rühle; Norbert Müller; Jean-François Rossignol; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

8.  Importance of substituents in ring opening: a DFT study on a model reaction of thiazole to thioamide.

Authors:  Xue Bai; Dan Qin; Lijun Yang
Journal:  J Mol Model       Date:  2021-02-21       Impact factor: 1.810

9.  Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.

Authors:  Roberto Canete; Angel A Escobedo; Maria E Gonzalez; Pedro Almirall
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

10.  Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae.

Authors:  Eliah R Shamir; Michelle Warthan; Sareena P Brown; James P Nataro; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.